The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Cancer-related Venous Thromboembolic Disease - Cohort Study
Official Title: Establishment of a Patient-based Cohort : Cancer-related Venous Thromboembolic Disease.
Study ID: NCT06393764
Brief Summary: Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.
Detailed Description: Cancer is associated with a higher risk of VTE and mortality. This association is characterized by various uncertainties at pathophysiological, diagnostic, therapeutic and prognostic levels. CAPE STUDY is a prospective, single-center interventional cohort follow-up study designed to investigate the risk of recurrence of VTE and its mechanisms in cancer patients. The study involves the collection of biological samples from cancer patients with venous thromboembolic disease. At inclusion and in case of recurrence of thrombosis or hemorrhage: * Blood samples will be taken for analysis and to constitute a biobank for future assays. * Urine samples will be collected Once a year for 5 years (and adapted to the clinical context): visit as part of routine care, or mailing of a questionnaire, or telephone contact.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Name: Françis Couturaud, Pr
Affiliation: CHU Brest
Role: PRINCIPAL_INVESTIGATOR